Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acoydase-Cold Tablets is an oral fixed-dose combination therapy developed by Bernard Biotech for the symptomatic relief of the common cold, nasal congestion, fever, and associated pain or body aches. The formulation contains five active ingredients: aceclofenac (a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase enzymes to reduce pain and inflammation), paracetamol (an analgesic and antipyretic), cetirizine hydrochloride (a second-generation H1 antihistamine that alleviates allergic symptoms like runny nose and sneezing), phenylephrine hydrochloride (a selective alpha-1 adrenergic receptor agonist that acts as a nasal decongestant), and caffeine (a central nervous system stimulant that acts as an analgesic adjuvant and helps counteract drowsiness caused by antihistamines).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Acoydase-Cold Tablets.